AGAATA delivers clinical reports in the fields of Reproductive Health, Oncology and Inherited Diseases.
Amsterdam, The Netherlands -6 th June 2018
AGAATA innovates a fully integrated and certified CE-IVD Diagnostic System with machine learning capabilities. AGAATA for clinical laboratories is designed to run in-house sensitive genetic tests delivering the fastest and accurate results. Machine learning is a subset of artificial intelligence in the field of computer programming that uses statistical techniques and acquisition of new information. AGAATA has the ability to learn and progressively improve performance on specificity and sensitivity.
The product will be introduced at the World Congress in Fetal Medicine which takes place this month in Athens.
AGAATA is a unique system for multiple diagnoses. It runs and monitors various genetic tests in connection with the different standard Next-Generation Sequencing equipment of clinical laboratories.
Elaborated interfaces assist the qualified decision maker with extensive information about each sample and machine learning tools accelerate the diagnosis.
A large portfolio of innovative tests based on DNA analysis for karyotyping, cancer predisposition, reproductive health and inherited diseases is accessible, benefiting of a robust, accurate, automated workflow comprising instruments and analysis software.
The scope includes all types of DNA, (Somatic and Germ Line from cfDNA, ctDNA and Genomic DNA) for karyotyping, Breast and Ovarian cancers, Colorectal cancers, Uterine, Gastric, Pancreatic, Melanoma, Prostate, Kidney and Bladder cancers as well as Cystic Fibrosis & B-Thalassemia and any other Gene panel.
The exclusive multi-layer operating AGAATA diagnostic system offers traceability, and standard laboratory equipment.
AGAATA provides powerful and automatized bioinformatics analysis to deliver comprehensive clinical reports, fully automated, with a short turnaround time. Therefore, this cutting edge turnkey solution accelerates any genetic laboratory, the only CE-IVD system with such a range of CE-IVD genetic tests.
Frederic Amar, CEO states: AGAATA is the next generation integrated smart system that offers most accurate and comprehensive analysis of the genome to empower laboratories, doctors and patients with most timely and relevant actionable genetic information contributing to a precise and personalized approach to patient care for both prevention and treatment. Installed in 30 minutes, AGAATA gives an immediate access to a large panel of genetic tests after a simple training session on the method in our research centre in Geneva. With AGAATA clinical laboratories can optimize their genetic platform and steer the whole process until results.
About CE-IVD
The CE-mark (CE-IVD) indicates that an IVD device complies with the European In Vitro Diagnostics Directive (98/79/EC), and that the device may be legally commercialized and distributed within the European Economic Area (EEA), which comprises the 27 European Union (EU) member states and Iceland, Liechtenstein, Norway and Switzerland as members of the European Free Trade Association (EFTA). The aim of the Directive is to ensure that IVDs consistently meet the performance levels specified by the manufacturer and do not compromise the health and safety of patients, users or third parties.
About ESPERITE
ESPERITE is a diversified biotech global group leader in regenerative and precision medicine. Established in 2000, the holding group is headquartered in the Netherlands, listed at Euronext Amsterdam and Paris and operational in almost 40 countries with a network of 6'000 clinics worldwide. ESPERITE transforms the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.
To learn more about the ESPERITE Group, or to book an interview with CEO Mr. Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com
***
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
Attachment
